Useful Resources

To better understand the specificities of ATMPs and navigate its complex ecosystem, this page collects a series of educational documents in different supports (videos, files, URLs, etc.).

Videos

Expert briefing sessions on cell and gene therapies – Playlist on the TRANSFORM YouTube channel

  • Modules 1&2: Understanding the promise of cell&gene therapies and its value for patients and healthcare system

  • Bakhuti Shengelia (Novartis) – Gene Therapies: Transforming the lives of patients today

  • Avril Daly (RI) – The value of cell&gene therapies for patients and healthcare systems

  • Prof. Francesco Muntoni (UCL) – Understanding the promise of cell&gene therapies

  • Brid Carberry (Novartis) – How are cell&gene therapies manufactured?

  • Module 3: How can we maximise the value of cell&gene therapies through early detection?

  • Martine Pergent (IPOPI) – How can we maximise the value of cell&gene therapies through early detection?

  • Tim Wilsdon (CRA) – How can we maximise the value of cell&gene therapies through early detection?

  • Module 4: Towards better use and exchange of RWE for cell&gene therapies

  • Elke Grooten (Novartis) – Towards better use and exchange of RWE for cell&gene therapies

  • Guillaume Byk (European Commission) – Towards better use and exchange of RWE for cell&gene therapies

  • Jo De Cock (INAMI-RIZIV) – Towards better use and exchange of RWE for cell&gene therapies

  • Prof Alessandra Ferlini (University of Ferrara) – Towards better use and exchange of RWE for cell&gene therapies

  • Alexander Natz (Secretary-General, EUCOPE) – Gene&cell therapy regulation and what it means for the revision of the pharma legislation

  • Martina Schussler-Lenz (Chair of EMA Committee for Advanced Therapies (CAT) – Gene&cell therapy regulation and what it means for the revision of the pharma legislation

  • Simone Boselli (Public Affairs Director, EURORDIS) – Gene&cell therapy regulation and what it means for the revision of the pharma legislation

  • MEP Pernille Weiss (EPP, DK); MEP Radka Maxova (S&D, CZ); Victor Maertens (Government Affairs Manager, EUCOPE) – How to make Europe more attractive for gene and cell therapy development?

  • Adam Hutchings (Managing Director, Dolon Consultancy) – How to make Europe more attractive for gene and cell therapy development?

  • Christina Kyriakopoulou (Senior Policy Officer, DG RTD) How to make Europe more attractive for cell and gene therapy development?

  • Frédéric Druck (Secretary General, essencia/bio.be) How to make Europe more attractive for cell and gene therapy development?

  • Victor Maertens (Government Affairs Manager, EUCOPE) How to make Europe more attractive for cell and gene therapy development?

Files

Academic articles, position papers, studies, etc. produced by TRANSFORM Alliance members

SIOPE-Market-Access-to-New-Anticancer-Medicines-for-Children-and-Adolescents-with-Cancer-in-EuropeDownload

@TRANSFORM_CGT on Twitter Follow us →

Interesting event @alliancerm today! With the EU Pharma legislation review, the new HTA Regulation and the EHDS, the EU has an opportunity to encourage innovation & ensure that ATMPs are a central part of the EU’s healthcare landscape @Kympouropoulos @susanasolisp #MEPsforATMPs https://t.co/ODkSdMePW9
29 November at 9:07pm
Reply Retweet
MEP @dieGamon endorses Recommendation 7️⃣ of the TRANSFORM MEP Charter, which calls for improved infrastructure and cross-border healthcare for ATMPs #MEPsforATMPs https://t.co/nDDxEhvqrr
22 November at 11:33am
Reply Retweet
Hear MEP @susanasolis outline Recommendation 6️⃣ of the TRANSFORM MEP Charter. Considering innovative access pathways for cell and gene therapies could help bring more ATMPs to #patients #MEPsforATMPs https://t.co/R8cs4snLL9
17 November at 10:25am
Reply Retweet